利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

39 条记录 (耗时 0.033 秒)

    Methods of inhibiting viral infection
    11.
    发明授权
    Methods of inhibiting viral infection 失效
    抑制病毒感染的方法

    公开(公告)号：US08207209B2

    公开(公告)日：2012-06-26

    申请号：US12256571

    申请日：2008-10-23

    申请人： Michael Kinch ,  Michael Goldblatt

    发明人： Michael Kinch ,  Michael Goldblatt

    IPC分类号： A61K31/4184

    CPC分类号： A61K31/4745 ,  A61K31/131 ,  A61K31/155 ,  A61K31/4184

    摘要： A method of inhibiting viral respiratory infection in a mammal in need of same, includes administering an effective amount of 2-[2-(5-carbamimidoyl-benzofuran-2-yl)-vinyl]-H-benzoimidazole-5-carboxamidine or the Bis-N-hydroxyamidine prodrug thereof, prior to viral infection, or therapeutically following viral infection, to inhibit that viral infection. The compound selectively inhibits Caspase 2 and/or 8 as to prevent infective viral particle release. It is optionally administered IV, IP, orally or via other conventional administration routes in a dosage range of 1 ng/kg-200 mg/kg of body weight.

    摘要翻译： 在需要相同的哺乳动物中抑制病毒呼吸道感染的方法包括给予有效量的2- [2-（5-甲脒基 - 苯并呋喃-2-基） - 乙烯基] -H-苯并咪唑-5-甲脒或 双-N-羟基脒前药，在病毒感染之前，或治疗性地在病毒感染之后，以抑制该病毒感染。 该化合物选择性地抑制胱天蛋白酶2和/或8以防止感染性病毒颗粒释放。 任选地以1ng / kg-200mg / kg体重的剂量范围以IV，IP口服或经由其它常规给药途径施用。

    METHOHDS OF INHIBITING VIRAL INFECTION
    12.
    发明申请
    METHOHDS OF INHIBITING VIRAL INFECTION 失效
    抑制病毒感染的甲基化

    公开(公告)号：US20090170890A1

    公开(公告)日：2009-07-02

    申请号：US12256571

    申请日：2008-10-23

    申请人： Michael Kinch ,  Michael Goldblatt

    发明人： Michael Kinch ,  Michael Goldblatt

    IPC分类号： A61K31/4745 ,  A61P31/12

    CPC分类号： A61K31/4745 ,  A61K31/131 ,  A61K31/155 ,  A61K31/4184

    摘要： A method of inhibiting viral infection in a mammal in need of same, includes administering an effective amount of at least one of the compounds of FGI-103 which are represented by 273, 365 and 510 either prophylactically to prevent viral infection, or therapeutically following viral infection. These compounds appear to selectively inhibit Caspase 8 as a method of preventing infective viral particle release. They can be administered IV, IP, orally or via other conventional administration routes. The compounds are highly effective, requiring relatively low dosages on the order of 1 ng/kg-200 mg/kg of body weight.

    摘要翻译： 在需要相同的哺乳动物中抑制病毒感染的方法包括以预防方式施用有效量的至少一种由273,355和510表示的FGI-103化合物，以预防病毒感染或治疗性病毒感染 感染。 这些化合物似乎选择性地抑制胱天蛋白酶8作为预防感染性病毒颗粒释放的方法。 它们可以IV，IP，口服或其他常规给药途径给药。 这些化合物是非常有效的，需要相当低的剂量约1ng / kg-200mg / kg体重。

    Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections
    13.
    发明申请
    Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections 审中-公开
    使用EphA2和EphrinA1调节剂治疗和预防感染

    公开(公告)号：US20060121043A1

    公开(公告)日：2006-06-08

    申请号：US11259266

    申请日：2005-10-27

    申请人： Michael Kinch ,  Kelly Carles-Kinch

    发明人： Michael Kinch ,  Kelly Carles-Kinch

    IPC分类号： A61K39/395

    CPC分类号： C07K16/2866 ,  A61K2039/505 ,  Y02A50/403 ,  Y02A50/41

    摘要： The present invention provides methods and compositions designed for the treatment, management, and/or amelioration of an infection, in particular an intracellular pathogen infection, such as a viral, bacterial, protozoa or fungal infection. In particular, the present invention provides methods for treating, managing, preventing and/or ameliorating an infection where the expression of EphA2 is upregulated in infected cells (e.g., infected epithelial cells), said methods comprising administering to a subject an effective amount of one or more EphA2/EphrinA1 Modulators. In accordance with the present invention, such methods may also comprise the administration of one or more therapies other than an EphA2/EphrinA1 Modulator. The present invention also provides pharmaceutical compositions comprising EphA2/EphrinA1 Modulators, and optionally, one or more prophylactic or therapeutic agents other than an EphA2/EphrinA1 Modulator, and the use of such compositions in the treating, management, prevention and/or amelioration of an infection. Further provided by the invention are articles of manufacture and kits comprising an EphA2/EphrinA1 Modulator of the invention, and, optionally, other prophylactic or therapeutic agents (e.g., immunomodulatory agents, anti-viral agents, anti-inflammatory agents, anti-bacterial agents, anti-fungal agents, etc.).

    摘要翻译： 本发明提供了用于治疗，管理和/或改善感染，特别是细胞内病原体感染如病毒，细菌，原生动物或真菌感染的方法和组合物。 特别地，本发明提供了用于治疗，控制，预防和/或改善感染的方法，其中EphA2的表达在受感染的细胞（例如感染的上皮细胞）中被上调，所述方法包括向受试者施用有效量的一种 或更多的EphA2 / EphrinA1调节剂。 根据本发明，这些方法还可以包括施用除EphA2 / EphrinA1调节剂之外的一种或多种治疗。 本发明还提供包含EphA2 / EphrinA1调节剂的药物组合物，以及任选的除EphA2 / EphrinA1调节剂之外的一种或多种预防或治疗剂，以及这些组合物在治疗，管理，预防和/或改善 感染。 本发明进一步提供的是包含本发明的EphA2 / EphrinA1调节剂和任选的其它预防或治疗剂（例如免疫调节剂，抗病毒剂，抗炎剂，抗菌剂 ，抗真菌剂等）。

    Targeted drug delivery using EphA2 or EphA4 binding moieties
    18.
    发明申请
    Targeted drug delivery using EphA2 or EphA4 binding moieties 审中-公开
    使用EphA2或EphA4结合部分的靶向药物递送

    公开(公告)号：US20050153923A1

    公开(公告)日：2005-07-14

    申请号：US11004794

    申请日：2004-12-03

    申请人： Michael Kinch

    发明人： Michael Kinch

    IPC分类号： A61K9/127 ,  A61K39/395 ,  A61K48/00

    CPC分类号： C07K16/2866 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K14/52 ,  C07K14/715 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/30 ,  A61K2300/00

    摘要： The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hyperproliferative cell disease, particularly cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, for the treatment, management, or prevention of hyperproliferative diseases, particularly cancer. In one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more therapeutic or prophylactic agents that treat or prevent a hyperproliferative disease, where the therapeutic or prophylactic agents are operatively associated with the delivery vehicle. In another embodiment, the method of the invention comprises administering to a subject a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or EphA4 targeting moiety and a therapeutic or prophylactic agent that treats or prevents a hyperproliferative disease. In yet another embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising a nucleotide sequence encoding an agent that treats or prevents a hyperproliferative disease, where the nucleic acid is operatively associated with the delivery vehicle. Pharmaceutical compositions are also provided by the present invention.

    摘要翻译： 本发明涉及设计用于治疗，控制或预防过度增殖性细胞疾病，特别是癌症的方法和组合物。 本发明的方法包括施用有效量的靶向表达Eph家族受体酪氨酸激酶（例如EphA2或EphA4）的细胞的组合物，用于治疗，控制或预防过度增殖性疾病，特别是癌症。 在一个实施方案中，本发明的方法包括向受试者施用包含与递送载体​​连接的EphA2或EphA4靶向部分的组合物，以及治疗或预防过度增殖性疾病的一种或多种治疗或预​​防剂，其中所述治疗或预防 试剂与输送载体可操作地相关联。 在另一个实施方案中，本发明的方法包括向受试者施用包含核酸的组合物，所述核酸包含编码EphA2或EphA4靶向部分的核苷酸序列和治疗或预防过度增殖性疾病的治疗或预防剂。 在另一个实施方案中，本发明的方法包括对受试者施用包含EphA2或EphA4靶向部分的组合物和包含编码治疗或预防过度增殖性疾病的药物的核苷酸序列的核酸，其中所述核酸可操作地相关联 与送货车。 药物组合物也由本发明提供。

    EphA2 T-cell epitope agonists and uses therefor
    19.
    发明申请
    EphA2 T-cell epitope agonists and uses therefor 审中-公开
    EphA2 T细胞表位激动剂及其用途

    公开(公告)号：US20050048550A1

    公开(公告)日：2005-03-03

    申请号：US10897711

    申请日：2004-07-22

    申请人： Walter Storkus ,  Michael Kinch

    发明人： Walter Storkus ,  Michael Kinch

    IPC分类号： A61K38/17 ,  C07K14/47 ,  C07K14/705 ,  G01N33/50 ,  G01N33/569 ,  C12Q1/68 ,  G01N33/574

    CPC分类号： C07K14/4748 ,  A61K38/1793 ,  A61K39/0011 ,  A61K2039/55566 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  G01N33/505 ,  G01N33/5091 ,  G01N33/56966 ,  G01N33/56972 ,  G01N2333/5409 ,  G01N2333/57

    摘要： EphA2 T-cell epitope agonists are provided herein. The agonists include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitope agonists are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The agonists also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 agonists also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.

    摘要翻译： 本文提供EphA2 T细胞表位激动剂。 激动剂包括对应于含有一个或多个T细胞表位的人EphA2蛋白的特异性片段的肽及其保守衍生物。 EphA2 T细胞表位激动剂可用于可用于确定和/或定量患者对EphA2的免疫反应性的测定中，例如ELISPOT测定。 激动剂也可用于调节患者对EphA2的免疫反应性的方法，其对于过表达EphA2的癌症如肾细胞癌（RCC）具有实际作用。 EphA2激动剂也可用于通过体内或离体方法对EphA2接种患者。